Any current/future new fundraising through debt or equity?

Mankind Pharma raised INR 10,000 crores in debt for the BSV acquisition, split into INR 5,000 crores of nonconvertible debentures (NCDs) and INR 5,000 crores of commercial papers (CPs) with varying tenures and interest rates. The company has shareholder approval for a potential equity raise aimed at retiring a portion of this debt to maintain a net debt-to-EBITDA ratio below 2x by FY '26. The proposed equity raise is expected to be close to INR 3,000 crores, pending formal Board approval. Debt repayment strategies include retiring debt using proceeds from non-core asset monetization (hospitali

Any current/future capex/capital investment/strategic investment?

Q2 FY'25 capex spend was INR128 crores, about 4.2% of total revenue, aligning with guidance of 4%-5%. The company aims to maintain this capex range in line with its growth strategy. Post-acquisition of BSV, integration efforts are underway with a roadmap expected to complete in next 2 quarters, indicating potential strategic investments in synergy realization. There are ongoing commercial excellence exercises to improve productivity and growth, implying investment in processes and possibly technology. No explicit mention of new large-scale capex projects, but strategic focus includes e

Future growth expectations in sales/revenue/volumes?

Mankind Pharma expects volume growth to improve from recent muted levels (1.3% in Q2 versus closer to 2% in Q1), aiming to outperform IPM consistently. Historically, volume growth was 4%-5%; the company hopes to return to this range over the next 2-3 years. Chronic segment is a key growth driver, currently contributing 36% of revenue, with an aspiration to exceed 40% in the short term and over 50% long term. Specialty and consumer care businesses have significant headroom and growth potential. Exports and international markets, including BSV acquisition, are expected to deliver strong double-d

Future growth expectations in earnings/operating earnings/profits/EPS?

Mankind Pharma expects double-digit revenue growth to continue, supported by chronic segment outperformance and strategic launches. EBITDA margin guidance is maintained at 25% to 26% for Mankind’s base business. The BSV acquisition is margin accretive with expected EBITDA margins higher than Mankind’s average, aiding overall margin improvement. Operating margin trajectory is expected to improve for both the base business and BSV due to chronic mix increase and operational levers. BSV's growth target is 15%+ with EBITDA margin improvements expected as synergies and MR productivity initiatives m

Mankind PharmaQ2 FY25Pharmaceuticals & Biotechnology

Mankind Pharma Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,535P/E: 47.9Market Cap: ₹1.0L CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Mankind Pharma expects volume growth to improve from recent muted levels (1.3% in Q2 versus closer to 2% in Q1), aiming to outperform IPM consistently.
Historically, volume growth was 4%-5%; the company hopes to return to this range over the next 2-3 years.
Chronic segment is a key growth driver, currently contributing 36% of revenue, with an aspiration to exceed 40% in the short term and over 50% long term.
Specialty and consumer care businesses have significant headroom and growth potential.
Exports and international markets, including BSV acquisition, are expected to deliver strong double-digit growth (15-20% internationally from FY26 onwards).
Overall revenue growth guidance remains double-digit.
Price erosion in some segments (e.g., emergency contraceptives) is a factor but volume remains intact.
Ongoing commercial excellence initiatives are aimed at boosting volume and sales further.

Margin guidance

Category 3

Mankind Pharma expects double-digit revenue growth to continue, supported by chronic segment outperformance and strategic launches.
EBITDA margin guidance is maintained at 25% to 26% for Mankind’s base business.
The BSV acquisition is margin accretive with expected EBITDA margins higher than Mankind’s average, aiding overall margin improvement.
Operating margin trajectory is expected to improve for both the base business and BSV due to chronic mix increase and operational levers.
BSV's growth target is 15%+ with EBITDA margin improvements expected as synergies and MR productivity initiatives materialize.
Chronic segment contribution aims to increase from 36% towards 40%+ in the short term and possibly over 50% in the long term, supporting consistent and profitable growth.
The company plans to maintain financial discipline with net debt-to-EBITDA ratio below 2x by FY26, supporting sustainable earnings growth.
EPS growth is supported by revenue growth, margin expansion, and operational efficiencies.

See what Mankind Pharma management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

Mankind Pharma raised INR 10,000 crores in debt for the BSV acquisition, split into INR 5,000 crores of nonconvertible debentures (NCDs) and INR 5,000 crores of commercial papers (CPs) with varying tenures and interest rates.
The company has shareholder approval for a potential equity raise aimed at retiring a portion of this debt to maintain a net debt-to-EBITDA ratio below 2x by FY '26.
The proposed equity raise is expected to be close to INR 3,000 crores, pending formal Board approval.
Debt repayment strategies include retiring debt using proceeds from non-core asset monetization (hospitality units) targeted at around INR 600-650 crores.
Overall, the company aims to fully liquidate INR 10,000 crores debt within 3 years through a mix of QIP (equity), asset sales, and operating cash flows.

Order book

The transcript does not provide any specific details regarding the current or expected order book or pending orders for Mankind Pharma Limited. The discussion primarily focuses on: - Volume growth trends and comparisons with IPM (Indian Pharmaceutical Market). - Impact of regulatory restrictions on particular products. - Specialty business performance and integration of the BSV acquisition. - Financial results including revenue, EBITDA margins, and debt raised for acquisitions. - Segmentation of domestic and international business growth. - Product portfolio expansion through in-licensed brands and new launches. No explicit information related to orderbook or pending orders was mentioned in the provided transcript.

See what Mankind Pharma management said on order book — free account, 30 seconds.

Capex plans

Yes

Q2 FY'25 capex spend was INR128 crores, about 4.2% of total revenue, aligning with guidance of 4%-5%.
The company aims to maintain this capex range in line with its growth strategy.
Post-acquisition of BSV, integration efforts are underway with a roadmap expected to complete in next 2 quarters, indicating potential strategic investments in synergy realization.
There are ongoing commercial excellence exercises to improve productivity and growth, implying investment in processes and possibly technology.
No explicit mention of new large-scale capex projects, but strategic focus includes expanding chronic therapy portfolio and specialty segments which may involve future capital allocation.
Non-core assets (hospitality units) are being liquidated to repay debt, reflecting a focus on optimizing capital structure rather than new investments currently.

Track Mankind Pharma — get its next earnings analysis in your feed

How does Mankind Pharma rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisMankind Pharma

Rev 3Mar 3

See where Mankind Pharma sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Mankind Pharma rank in Pharmaceuticals & Biotechnology?

Compare Mankind Pharma against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Mankind Pharma's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Mankind Pharma Q2 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Mankind Pharma rank in Pharmaceuticals & Biotechnology?

Continue your research

What Mankind Pharma's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season